blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1692113

EP1692113 - ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.08.2018
Database last updated on 27.07.2024
FormerThe patent has been granted
Status updated on  25.08.2017
FormerGrant of patent is intended
Status updated on  18.04.2017
Most recent event   Tooltip29.05.2020Lapse of the patent in a contracting state
New state(s): PT		published on 01.07.2020  [2020/27]
Applicant(s)For all designated states
Aptose Biosciences Inc.
5955 Airport Road, Suite 228
Mississauga, ON L4V 1R9 / CA
[2018/11]
Former [2017/39]For all designated states
Lorus Therapeutics Inc.
2 Meridian Road
Toronto, Ontario M9W 4Z7 / CA
Former [2009/32]For all designated states
Lorus Therapeutics Inc.
2 Meridian Road
Toronto, Ontario M9W 4Z7 / CA
Former [2007/44]For all designated states
GeneSense Technologies Inc.
2 Meridian Road
Toronto, Ontario M9W 4Z7 / CA
Former [2006/34]For all designated states
Lorus Therapeutics Inc.
2 Meridian Road
Toronto, Ontario M9W 4Z7 / CA
Inventor(s)01 / HUESCA, Mario
26 Harris Park Drive
Toronto, Ontario M1L 3A2 / CA
02 / AL-QAWASMEH, Raed
15 Vicora Linkway Apt. 1004
North York, Ontario M3C 1A8 / CA
03 / YOUNG, Aiping, H.
201 Senlac Road
North York, Ontario M2R 1P3 / CA
04 / LEE, Yoon
2219 Corsair Road
Mississauga, Ontario L5A 2L7 / CA
05 / LOCK Lisa
49 Devon Road
Toronto, Ontario, M4E 2J7 / CA
 [2007/44]
Former [2006/34]01 / HUESCA, Mario
26 Harris Park Drive
Toronto, Ontario M1L 3A2 / CA
02 / AL-QAWASMEH, Raed
15 Vicora Linkway Apt. 1004
North York, Ontario M3C 1A8 / CA
03 / YOUNG, Aiping, H.
201 Senlac Road
North York, Ontario M2R 1P3 / CA
04 / LEE, Yoon
2219 Corsair Road
Mississauga, Ontario L5A 2L7 / CA
Representative(s)Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ / GB
[N/P]
Former [2017/39]Cooley (UK) LLP
Dashwood
69 Old Broad Street
London EC2M 1QS / GB
Former [2006/34]Samuels, Lucy Alice
Gill Jennings & Every LLP Broadgate House 7 Eldon Street
London EC2M 7LH / GB
Application number, filing date04799154.215.11.2004
[2006/34]
WO2004IB52433
Priority number, dateUS20030520279P14.11.2003         Original published format: US 520279 P
US20040599509P06.08.2004         Original published format: US 599509 P
[2006/34]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2005047266
Date:26.05.2005
Language:EN
[2005/21]
Type: A1 Application with search report 
No.:EP1692113
Date:23.08.2006
Language:EN
The application published by WIPO in one of the EPO official languages on 26.05.2005 takes the place of the publication of the European patent application.
[2006/34]
Type: B1 Patent specification 
No.:EP1692113
Date:27.09.2017
Language:EN
[2017/39]
Search report(s)International search report - published on:EP26.05.2005
ClassificationIPC:C07D233/54, C07D235/02, C07D401/04, C07D401/14, C07D403/04, C07D403/14, C07D405/14, C07D409/14, C07D471/04, C07D471/14, C07D495/04, A61K31/4164, A61K31/4178, A61K31/4184, A61K31/4188
[2008/25]
CPC:
A61K31/4184 (EP,US); A61K31/4178 (EP,US); A61K31/4188 (EP,US);
A61K31/4745 (EP,US); A61P35/00 (EP); A61P35/02 (EP);
A61P43/00 (EP); C07D233/64 (EP,US); C07D235/02 (EP,US);
C07D401/14 (EP,US); C07D403/04 (EP,US); C07D403/14 (EP,US);
C07D409/14 (EP,US); C07D495/04 (EP,US) (-)
Former IPC [2006/34]C07D233/58, C07D235/02, C07D401/04, C07D401/14, C07D403/04, C07D403/14, C07D405/14, C07D409/14, C07D471/04, C07D471/14, C07D495/04, A61K31/4164, A61K31/4178, A61K31/4184, A61K31/4188
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2017/39]
Former [2006/34]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LU,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:ARYLIMIDAZOLE UND DEREN VERWENDUNG ALS ANTIKREBSMITTEL[2006/34]
English:ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS[2006/34]
French:IMIDAZOLES D'ARYLE ET LEUR UTILISATION COMME AGENTS ANTICANCEREUX[2006/34]
Entry into regional phase06.06.2006National basic fee paid 
06.06.2006Designation fee(s) paid 
06.06.2006Examination fee paid 
Examination procedure06.06.2006Amendment by applicant (claims and/or description)
06.06.2006Examination requested  [2006/34]
24.10.2007Despatch of a communication from the examining division (Time limit: M06)
06.05.2008Reply to a communication from the examining division
16.08.2010Despatch of a communication from the examining division (Time limit: M06)
28.02.2011Reply to a communication from the examining division
16.10.2013Despatch of a communication from the examining division (Time limit: M06)
28.04.2014Reply to a communication from the examining division
21.04.2015Despatch of a communication from the examining division (Time limit: M06)
30.10.2015Reply to a communication from the examining division
28.04.2016Despatch of a communication from the examining division (Time limit: M04)
08.09.2016Reply to a communication from the examining division
18.04.2017Communication of intention to grant the patent
16.08.2017Fee for grant paid
16.08.2017Fee for publishing/printing paid
16.08.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  24.10.2007
Opposition(s)28.06.2018No opposition filed within time limit [2018/36]
Fees paidRenewal fee
28.11.2006Renewal fee patent year 03
26.11.2007Renewal fee patent year 04
27.11.2008Renewal fee patent year 05
27.11.2009Renewal fee patent year 06
12.11.2010Renewal fee patent year 07
29.11.2011Renewal fee patent year 08
13.11.2012Renewal fee patent year 09
18.11.2013Renewal fee patent year 10
21.10.2014Renewal fee patent year 11
30.11.2015Renewal fee patent year 12
28.11.2016Renewal fee patent year 13
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU15.11.2004
CY27.09.2017
CZ27.09.2017
EE27.09.2017
ES27.09.2017
FI27.09.2017
IT27.09.2017
MC27.09.2017
PL27.09.2017
PT27.09.2017
RO27.09.2017
SE27.09.2017
SI27.09.2017
SK27.09.2017
TR27.09.2017
LU15.11.2017
BG27.12.2017
GR28.12.2017
IS27.01.2018
[2020/27]
Former [2020/16]HU15.11.2004
CY27.09.2017
CZ27.09.2017
EE27.09.2017
ES27.09.2017
FI27.09.2017
IT27.09.2017
MC27.09.2017
PL27.09.2017
RO27.09.2017
SE27.09.2017
SI27.09.2017
SK27.09.2017
TR27.09.2017
LU15.11.2017
BG27.12.2017
GR28.12.2017
IS27.01.2018
Former [2019/46]HU15.11.2004
CY27.09.2017
CZ27.09.2017
EE27.09.2017
ES27.09.2017
FI27.09.2017
IT27.09.2017
MC27.09.2017
PL27.09.2017
RO27.09.2017
SE27.09.2017
SI27.09.2017
SK27.09.2017
LU15.11.2017
BG27.12.2017
GR28.12.2017
IS27.01.2018
Former [2019/31]HU15.11.2004
CZ27.09.2017
EE27.09.2017
ES27.09.2017
FI27.09.2017
IT27.09.2017
MC27.09.2017
PL27.09.2017
RO27.09.2017
SE27.09.2017
SI27.09.2017
SK27.09.2017
LU15.11.2017
BG27.12.2017
GR28.12.2017
IS27.01.2018
Former [2018/52]CZ27.09.2017
EE27.09.2017
ES27.09.2017
FI27.09.2017
IT27.09.2017
MC27.09.2017
PL27.09.2017
RO27.09.2017
SE27.09.2017
SI27.09.2017
SK27.09.2017
LU15.11.2017
BG27.12.2017
GR28.12.2017
IS27.01.2018
Former [2018/39]CZ27.09.2017
EE27.09.2017
ES27.09.2017
FI27.09.2017
IT27.09.2017
MC27.09.2017
PL27.09.2017
RO27.09.2017
SE27.09.2017
SK27.09.2017
LU15.11.2017
BG27.12.2017
GR28.12.2017
IS27.01.2018
Former [2018/33]CZ27.09.2017
EE27.09.2017
ES27.09.2017
FI27.09.2017
IT27.09.2017
MC27.09.2017
RO27.09.2017
SE27.09.2017
SK27.09.2017
BG27.12.2017
GR28.12.2017
IS27.01.2018
Former [2018/24]CZ27.09.2017
EE27.09.2017
ES27.09.2017
FI27.09.2017
IT27.09.2017
RO27.09.2017
SE27.09.2017
SK27.09.2017
BG27.12.2017
GR28.12.2017
IS27.01.2018
Former [2018/23]CZ27.09.2017
EE27.09.2017
ES27.09.2017
FI27.09.2017
RO27.09.2017
SE27.09.2017
SK27.09.2017
BG27.12.2017
GR28.12.2017
IS27.01.2018
Former [2018/21]CZ27.09.2017
FI27.09.2017
SE27.09.2017
BG27.12.2017
GR28.12.2017
Former [2018/12]FI27.09.2017
SE27.09.2017
BG27.12.2017
GR28.12.2017
Former [2018/10]FI27.09.2017
SE27.09.2017
Former [2018/08]FI27.09.2017
Cited inInternational search[X]WO03087026  (HOFFMANN LA ROCHE [CH]) [X] 1-17 * page 14, line 1 - line 6; example -; claim - *;
 [X]WO03066579  (AXYS PHARMACEUTICALS [US], et al) [X] 1-17 * claim - *;
 [X]WO02072576  (PFIZER PROD INC [US], et al) [X] 1-17 * claims; examples 63-65,67,68,70-103,105-141,145,148,149,151,154,155,158,159,161,263-290,317,319-322 *;
 [X]WO0126467  (ONTOGEN CORP [US], et al) [X] 1-17 * claim 1 *;
 [X]WO0224680  (SMITHKLINE BEECHAM PLC [GB], et al) [X] 1-17 * page 10, line 10 - page 11, line 11; examples 4-7,14-23; claims 1,11 *;
 [X]WO0059541  (SANKYO CO [JP], et al) [X] 1-17 * abstract *;
 [X]WO9907701  (SUGEN INC [US]) [X] 1-17 * example 3; claims 1-6,14,15; compound 235 *;
 [X]EP0812829  (ONTOGEN CORP [US]) [X] 1-17 * example -; claim - *;
 [X]WO9902155  (ONTOGEN CORP [US]) [X] 1-17 * claims 1-52,55-63,70,71 *;
 [X]WO9736587  (MERCK & CO INC [US], et al) [X] 1-17 * claims 5,7-9 *;
 [X]US3279918  (MARIA CASSIERS PAUL, et al) [X] 13,14 * column 1, line 24 - column 2, line 22; table 1; compounds 11-37 *
Examination   - Min Guan ET AL, "Bright red light-emitting electroluminescence devices based on a functionalized europium complex", New Journal of Chemistry, (20030101), vol. 27, no. 12, doi:10.1039/b305361j, ISSN 1144-0546, page 1731, XP055083545

DOI:   http://dx.doi.org/10.1039/b305361j
    - Ya Xiong ET AL, "Interaction of polypyridyl ruthenium(II) complexes containing non-planar ligands with DNA", Journal of the Chemical Society, Dalton Transactions, (19990101), no. 1, doi:10.1039/a806170j, ISSN 0300-9246, pages 19 - 24, XP055083547

DOI:   http://dx.doi.org/10.1039/a806170j
    - XU H ET AL, "Synthesis and spectroscopic RNA binding studies of [Ru(phen)2MHPIP]<2+> ", INORGANIC CHEMISTRY COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 6, no. 6, ISSN 1387-7003, (20030601), pages 766 - 768, (20030601), XP027113034
    - GAO D ET AL, "Synthesis and electroluminescence properties of an organic europium complex", JOURNAL OF ALLOYS AND COMPOUNDS, ELSEVIER SEQUOIA, LAUSANNE, CH, (20030825), vol. 358, no. 1-2, doi:10.1016/S0925-8388(03)00048-3, ISSN 0925-8388, pages 188 - 192, XP004448427

DOI:   http://dx.doi.org/10.1016/S0925-8388(03)00048-3
    - Hong Xu ET AL, "Effects of the ancillary ligands of polypyridyl ruthenium(ii) complexes on the DNA-binding behaviors", New Journal of Chemistry, (20030101), vol. 27, no. 8, doi:10.1039/b212826h, ISSN 1144-0546, page 1255, XP055083557

DOI:   http://dx.doi.org/10.1039/b212826h
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.